Skip to Main Content

Good morning, everyone, and how are you today? We are doing just fine, thank you, despite the soggy skies overhead. After all, as the Morning Mayor used to say: “Every new day should be unwrapped like a precious gift.” So while you tug on the ribbon, we will brew another cup of stimulation — chocolate raspberry is our choice — and continue foraging for items of interest. Speaking of which, here is the latest selection. Meanwhile, we hope you have a smashing day and achieve all your goals. One small note, we will back on Thursday as we sequester tomorrow to observe ancient rituals. A colleague will be here in our stead. Ta-ta!

The U.S. Supreme Court asked the Biden administration for an opinion on whether it should hear a challenge by Teva Pharmaceuticals to a $235 million award to GlaxoSmithKline in a patent dispute over generic heart medication, Reuters notes. Teva appealed a lower court ruling that reinstated the jury award for GSK. The case could affect the future of so-called “skinny labels,” which allow generic drugmakers to avoid patent lawsuits if a generic drug label omits potentially infringing uses of a brand-name drug. Teva has argued that it followed U.S. Food and Drug Administration instructions to “carve out” from its label a patented method for using the drug to treat heart failure.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment